Nuzenio

Tradingview Srpt

Tradingview Srpt entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 9 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated - TradingViewTradingView · Thu, 06 Aug 2026 18:05:00 GMTSRPT: Q2 profitability and cash growth support narrowed 2026 guidance amid stable Duchenne demand - TradingViewTradingView · Wed, 05 Aug 2026 23:23:15 GMTSarepta Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Wed, 05 Aug 2026 21:01:54 GMTSRPT: Q2 2026 delivered profitability, strong cash flow, and narrowed FY 2026 revenue guidance - TradingViewTradingView · Wed, 05 Aug 2026 20:47:17 GMTSRPT: Q2 2026 delivered operating profitability on $328.7M revenue, but sales fell 34% year-over-year - TradingViewTradingView · Wed, 05 Aug 2026 20:11:27 GMTSarepta Therapeutics 2Q 2026: Revenue $328.7M, EPS $(0.05) — 10-Q Summary - TradingViewTradingView · Wed, 05 Aug 2026 20:11:00 GMTSRPT: Q2 2026 revenues dropped 34% year-over-year as ELEVIDYS sales declined sharply after safety events - TradingViewTradingView · Wed, 05 Aug 2026 20:09:40 GMTSRPT Q2'26 Earnings: EPS estimate is 0.22 USD - TradingViewTradingView · Tue, 04 Aug 2026 11:01:05 GMT

Timeline

Thu, 06 Aug 2026 18:05:00 GMTSarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated - TradingView
Wed, 05 Aug 2026 23:23:15 GMTSRPT: Q2 profitability and cash growth support narrowed 2026 guidance amid stable Duchenne demand - TradingView
Wed, 05 Aug 2026 21:01:54 GMTSarepta Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingView
Wed, 05 Aug 2026 20:47:17 GMTSRPT: Q2 2026 delivered profitability, strong cash flow, and narrowed FY 2026 revenue guidance - TradingView
Wed, 05 Aug 2026 20:11:27 GMTSRPT: Q2 2026 delivered operating profitability on $328.7M revenue, but sales fell 34% year-over-year - TradingView
Wed, 05 Aug 2026 20:11:00 GMTSarepta Therapeutics 2Q 2026: Revenue $328.7M, EPS $(0.05) — 10-Q Summary - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Srpt.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.